Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17705192 | 0.81 | CCR5 (0.53) | HTTLMNARAB9ASMPD1ALDH1A1 | |
| SCHEMBL16307065 | 0.81 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL16306981 | 0.81 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL16306931 | 0.81 | CYSLTR2 (0.51) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL16306936 | 0.78 | CYSLTR2 (0.52) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL16306953 | 0.77 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL16307011 | 0.77 | CYSLTR2 (0.58) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL16306952 | 0.76 | SMN1; SMN2 (0.50) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL15462636 | 0.74 | HPGD (0.51) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A | |
| SCHEMBL2772497 | 0.73 | SMN1; SMN2 (0.49) | CYSLTR2CYSLTR1NPSR1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2014201073-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | CYSLTR2 2550/4885CYSLTR1 2893/4885NPSR1 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.